Persistent Hyperglycemia in a Truck Driver With CKD
58-year-old man with type 2 diabetes for 9 years, BMI 33, hypertension, and CKD (eGFR 42 mL/min/1.73 m², UACR 350 mg/g). HbA1c 9.4%. Medications: metformin 1,000 mg twice daily, glipizide 5 mg daily, lisinopril 20 mg daily, atorvastatin 40 mg daily. No ASCVD history. Two self-reported hypoglycemia episodes in the past 3 months (glucose 54 and 58 mg/dL) after skipped meals. He works as a truck driver and worries that hypoglycemia will jeopardize his commercial license. He checks glucose only once daily, before breakfast. He is reluctant to start injectable therapy and wants “one more pill.” BP 142/88 mm Hg. He has not had a retinal exam or foot exam in 2 years. He has no symptoms of heart failure. Potassium 4.8 mmol/L, creatinine 1.6 mg/dL.
1. Which glucose-lowering changes are indicated now, and why?
Read the worked answer
Stop glipizide. Sulfonylureas cause hypoglycemia, and he has already had two episodes, one while working as a commercial driver; CKD increases risk. Reduce metformin to no more than 1,000 mg/day because eGFR is 30–45; continue only if renal function is stable and counsel sick-day rules. Add an SGLT2 inhibitor (empagliflozin 10 mg or dapagliflozin 10 mg) for kidney and cardiovascular protection; it is oral, which addresses his preference, and can be started at this eGFR. It will lower A1c only modestly at eGFR 42, so anticipate needing a GLP-1 receptor agonist if A1c remains above his individualized goal (likely below 8% given hypoglycemia risk). Do not start basal insulin now because of his driving license and hypoglycemia history. Recheck BMP in 2–4 weeks and A1c in 3 months.
2. What monitoring and safety counseling does he need in the next 3 months?
Read the worked answer
After stopping glipizide and reducing metformin, review glucose logs and ask specifically about nocturnal and driving-related hypoglycemia. After SGLT2 initiation, check BMP in 2–4 weeks for creatinine, potassium, and volume status; expect a small reversible eGFR dip. Counsel on genital mycotic infections, urinary tract infections, and euglycemic ketoacidosis; give sick-day rules (hold metformin and SGLT2 during vomiting, dehydration, or acute illness). Continue lisinopril and atorvastatin; recheck UACR and potassium. Arrange dilated eye exam and comprehensive foot exam. Because he drives commercially, document that he is no longer on a sulfonylurea and review hypoglycemia symptoms and glucose monitoring before driving. A1c in 3 months; if above goal, revisit GLP-1.
3. How would you address his reluctance to injectables?
Read the worked answer
Start with his preference: an oral SGLT2 inhibitor now respects it and provides renal and cardiac benefit. Be transparent that at A1c 9.4% and eGFR 42, SGLT2 alone is unlikely to reach goal, so we are buying time and protecting organs, not pretending one pill will fix everything. Set an individualized target, probably below 8%, because he has CKD and hypoglycemia risk. Explain that a GLP-1 receptor agonist is injectable but has strong A1c and weight benefits and low hypoglycemia risk; demonstrate a pen and show that many patients prefer it once they try it. Address his license fears: GLP-1 agents rarely cause hypoglycemia unless combined with insulin or a sulfonylurea. If he still declines, consider a DPP-4 inhibitor as a weaker oral option, but prioritize SGLT2 and later GLP-1.